Frontiers in Immunology (Jul 2024)
Immune dysregulation is an important factor in the underlying complications in Influenza infection. ApoH, IL-8 and IL-15 as markers of prognosis
- Sara Garcinuño,
- Sara Garcinuño,
- Antonio Lalueza,
- Antonio Lalueza,
- Antonio Lalueza,
- Antonio Lalueza,
- Francisco Javier Gil-Etayo,
- Francisco Javier Gil-Etayo,
- Raquel Díaz-Simón,
- Raquel Díaz-Simón,
- Ignacio Lizasoain,
- Ignacio Lizasoain,
- Ana Moraga,
- Ana Moraga,
- Blanca Diaz-Benito,
- Laura Naranjo,
- Laura Naranjo,
- Oscar Cabrera-Marante,
- Oscar Cabrera-Marante,
- Daniel Enrique Pleguezuelo,
- Daniel Enrique Pleguezuelo,
- Maria Ruiz-Ruigomez,
- Maria Ruiz-Ruigomez,
- Blanca Ayuso,
- Estibaliz Arrieta,
- Dolores Folgueira,
- Dolores Folgueira,
- Dolores Folgueira,
- Estela Paz-Artal,
- Estela Paz-Artal,
- Estela Paz-Artal,
- Cecilia Cueto,
- Carlos Lumbreras,
- Carlos Lumbreras,
- Carlos Lumbreras,
- Carlos Lumbreras,
- Antonio Serrano,
- Antonio Serrano,
- Antonio Serrano,
- Manuel Serrano,
- Manuel Serrano
Affiliations
- Sara Garcinuño
- Healthcare Research Institute Hospital 12 de Octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain
- Sara Garcinuño
- Immunology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
- Antonio Lalueza
- Healthcare Research Institute Hospital 12 de Octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain
- Antonio Lalueza
- Internal Medicine Department, Hospital Universitario 12 de Octubre, Madrid, Spain
- Antonio Lalueza
- Faculty of Medicine, Universidad Complutense, Madrid, Spain
- Antonio Lalueza
- Red de Infecciones en Inmunodeprimidos no VIH e infecciones relacionadas con la asistencia sanitaria (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
- Francisco Javier Gil-Etayo
- Healthcare Research Institute Hospital 12 de Octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain
- Francisco Javier Gil-Etayo
- Immunology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
- Raquel Díaz-Simón
- Healthcare Research Institute Hospital 12 de Octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain
- Raquel Díaz-Simón
- Internal Medicine Department, Hospital Universitario 12 de Octubre, Madrid, Spain
- Ignacio Lizasoain
- Healthcare Research Institute Hospital 12 de Octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain
- Ignacio Lizasoain
- Faculty of Medicine, Universidad Complutense, Madrid, Spain
- Ana Moraga
- Healthcare Research Institute Hospital 12 de Octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain
- Ana Moraga
- Cell Biology Department, Faculty of Medicine, Universidad Complutense, Madrid, Spain
- Blanca Diaz-Benito
- Healthcare Research Institute Hospital 12 de Octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain
- Laura Naranjo
- Healthcare Research Institute Hospital 12 de Octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain
- Laura Naranjo
- Immunology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
- Oscar Cabrera-Marante
- Healthcare Research Institute Hospital 12 de Octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain
- Oscar Cabrera-Marante
- Immunology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
- Daniel Enrique Pleguezuelo
- Healthcare Research Institute Hospital 12 de Octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain
- Daniel Enrique Pleguezuelo
- Immunology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
- Maria Ruiz-Ruigomez
- Healthcare Research Institute Hospital 12 de Octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain
- Maria Ruiz-Ruigomez
- Internal Medicine Department, Hospital Universitario 12 de Octubre, Madrid, Spain
- Blanca Ayuso
- Internal Medicine Department, Hospital Universitario 12 de Octubre, Madrid, Spain
- Estibaliz Arrieta
- Internal Medicine Department, Hospital Universitario 12 de Octubre, Madrid, Spain
- Dolores Folgueira
- Healthcare Research Institute Hospital 12 de Octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain
- Dolores Folgueira
- Faculty of Medicine, Universidad Complutense, Madrid, Spain
- Dolores Folgueira
- Microbiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
- Estela Paz-Artal
- Healthcare Research Institute Hospital 12 de Octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain
- Estela Paz-Artal
- Immunology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
- Estela Paz-Artal
- Faculty of Medicine, Universidad Complutense, Madrid, Spain
- Cecilia Cueto
- Biochemistry Department, Hospital Universitario 12 de Octubre, Madrid, Spain
- Carlos Lumbreras
- Healthcare Research Institute Hospital 12 de Octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain
- Carlos Lumbreras
- Internal Medicine Department, Hospital Universitario 12 de Octubre, Madrid, Spain
- Carlos Lumbreras
- Faculty of Medicine, Universidad Complutense, Madrid, Spain
- Carlos Lumbreras
- Red de Infecciones en Inmunodeprimidos no VIH e infecciones relacionadas con la asistencia sanitaria (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
- Antonio Serrano
- Healthcare Research Institute Hospital 12 de Octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain
- Antonio Serrano
- Immunology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
- Antonio Serrano
- Red de Centros de Investigación Biomédica en Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- Manuel Serrano
- Healthcare Research Institute Hospital 12 de Octubre (imas12), Hospital Universitario 12 de Octubre, Madrid, Spain
- Manuel Serrano
- Immunology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
- DOI
- https://doi.org/10.3389/fimmu.2024.1443096
- Journal volume & issue
-
Vol. 15
Abstract
IntroductionInfluenza virus infection can cause a range of clinical symptoms, including respiratory failure (RF) and even death. The mechanisms responsible for the most severe forms of the disease are not yet well understood. The objective is to assess the initial immune response upon admission and its potential impact on infection progression.MethodsWe conducted a prospective observational study of patients with influenza virus infection who required admission to a tertiary hospital in the 2017/18 and 2018/19 flu seasons. Immune markers, surrogate markers of neutrophil activation, and blood levels of DNase I and Apolipoprotein-H (ApoH) were determined in the first serum sample available during hospital care. Patients were followed until hospital discharge or death. Initially, 792 patients were included. From this group, 107 patients with poor evolution were selected, and a random control group was matched by day of admission.ResultsPatients with poor outcomes had significantly reduced ApoH levels, a soluble protein that regulate both complement and coagulation pathways. In multivariate analysis, low plasma levels of ApoH (OR:5.43; 2.21-13.4), high levels of C- reactive protein (OR:2.73: 1.28-5.4), hyperferritinemia (OR:2.83; 1.28-5.4) and smoking (OR:3.41; 1.04-11.16), were significantly associated with a worse prognosis. RF was independently associated with low levels of ApoH (OR: 5.12; 2.02-1.94), while high levels of IL15 behaved as a protective factor (OR:0.30; 0.12-0.71).DiscussionTherefore, in hospitalized influenza patients, a dysregulated early immune response is associated with a worse outcome. Adequate plasma levels of ApoH are protective against severe influenza and RF and High levels of IL15 protect against RF.
Keywords